Mechanisms of the hypoglycemic effects of the α2-adrenoceptor antagonists SL84.0418 and deriglidole

Life Sciences

Volumn 62, Issue 9, 1998, Pages 839-852

  Guillot, Etienne ^a   Coste, Annick ^a   Eon, Marie Therèse ^a   Angel, Itzchak ^a  

^a SANOFI   (France)

Author keywords

2 adrenoceptors; Chlorisondamine; Deriglidole; Diabetes mellitus; Diazoxide; Insulin release; Propranol; SL84.0418; SL86.0714

Indexed keywords

1,2,4,5 TETRAHYDRO 2 (2 IMIDAZOLIN 2 YL) 2 PROPYLPYRROLO[3,2,1 HI]INDOLE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DERIGLIDOLE; PROPRANOLOL; SL 860714; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; ENANTIOMER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BLOOD GLUCOSE; CHLORISONDAMINE; DIABETES MELLITUS, EXPERIMENTAL; DIAZOXIDE; FEMALE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INDOLES; INSULIN; INSULIN ANTAGONISTS; MALE; MICE; NOREPINEPHRINE; PROPRANOLOL; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; SPECIES SPECIFICITY;

ANIMALIA;

EID: 0032559249     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)01186-7     Document Type: Article

References (16)

1. 1. S. Z. LANGER, Pharmacol. Rev. 32 337-362 (1981).
2. 2. J. C. HENQUIN, S. CHARLES, N. NENQUIN, F. MATHOT and T. TAMAGAWA, Diabetes 31 776-783 (1982).
3. 3. A. SCHULTZ and A. HASSELBLATT, Naunyn-Schmied. Arch. Pharmacol, 340 305-309 (1989)
4. 4. T. D. PLANT and J. C. HENQUIN, Br. J. Pharmacol. 101 115-120 (1990).
5. 5. S. L F. CHAN, M. J. DUNNE, M. R. STILLINGS and M N. G. ORGAN, Eur. J. Pharmacol. 204 :41-48 (1991).
6. 6. S. L. F. CHAN, C. A. BROWN and N. G. and MORGAN, Eur. J. Pharmacol. 230 : 375-378 (1993).
7. 7. J. C. JONAS, T. D. PLANT and J. C. HENQUIN, Br. J. Pharmacol. 107 8-14 (1992).
8. 8. J. C. JONAS, T. D. PLANT, I. ANGEL, S. Z. LANGER and J.C. HENQUIN, Eur. J. Pharmacol. 254 27-33 (1994).
9. 9. I. ANGEL, H. SCHOEMAKER, S. ARBILLA, A. M. GALZIN, C. BERRY, R. NIDDAM, C. PIMOULE, M. SEVRIN, A. WICK, A. and S.Z. LANGER, J. Pharmacol. Exp. Ther. 263 1327-1333 (1992).
10. 10. I. ANGEL, A. GROSSET, G. PERRAULT, H. SCHOEMAKER and S.Z. LANGER, Eur. J. Pharmacol. 234 137-145 (1993).
11. 11. J. C. JONAS, M-J. GARCIA-BARRATO, LANGEL and J.C. HENQUIN, Eur. J. Pharmacol. 264 81-84 (1994).
12. 12. E. GUILLOT, COSTE and I. ANGEL, Life Sciences 57 2081-2090 (1995).
13. 13. I. BERLIN, P. ROSENWEIG, S. CHALON, F E. USEAU, C. LANDAULT, F. CESSELIN, C. BLACKER and A. J. PUECH, Clin. Pharmacol. Ther. 55 338-345 (1994).
14. 14. M. TAOUIS, M. BERLAN, P. MONTASTRUC and M. LAFONTAN. J.Pharmacol. Exp. Ther. 247 1172-1180 (1988).
15. 15. S. L. F. CHAN, C. A. BROWN, K. E. SCARPELLO and N. G. MORGAN, Br. J. Pharmacol. 112 1065-1070 (1994).
16. 16. L. ELIASSON, E. RENSTRÖM, C. ÄMMÄLÄ, P-O. BERGGREN, A. M. BORTERELLO, K. BOKVIST, A. CHIBALIN, J. T. DEENEY, P. R. FLATT, J. GÄBEL, J. GROMADA, O. LARSSON, P. LINDSTRÖM, C. J. RHODES, and P RORSMAN, Science 271 813-815 (1996).